Sign In
Get Clay Free →

Suggestions

    Kui Shen

    Director of Clinical Statistics at Bayer - Bayer Science Fellow - Precision Medicine - CDx - ML/AI

    Professional Background

    Kui Shen is a highly skilled and multi-talented statistician and data scientist with a decade of rich experience in the pharmaceutical industry, particularly in the area of clinical development. With profound knowledge spanning both early-stage clinical development and comprehensive late-stage pre-market approval applications, Kui has demonstrated expertise that significantly impacts drug discovery and the overall medical research ecosystem.

    As the Director of Clinical Statistics at Bayer Pharmaceuticals, Kui Shen plays a pivotal role in leading statistical strategies that support critical drug development processes. Known for a systematic approach that harnesses both Bayesian and frequentist statistical methods, Kui has effectively contributed to various projects, enhancing outcomes in clinical and operational aspects of studies. This role marks a continuation of a stellar trajectory at Bayer, where Kui has also held positions as a Bayer Science Fellow, Associate Director of Clinical Statistics, and Deputy Director of Clinical Statistics.

    Prior to joining Bayer, Kui's professional journey includes significant roles at AstraZeneca as Scientist II, where advanced statistical methods were employed to inform drug development decisions. Before that, Kui was lead statistician at Medical Science & Computing (MSC), utilizing a robust statistical framework to bolster research initiatives. Additionally, Kui's early career saw extensive hands-on experience with Precision Therapeutics Inc, where a combination of internships and full-time positions laid a solid foundation for statistical acumen and leadership.

    Education and Achievements

    Kui Shen's academic credentials include a Doctorate in Philosophy (PhD) focusing on Computational Biology and Statistics, where academic rigor met real-world applicability at the prestigious University of Pittsburgh and Carnegie Mellon University. This education equipped Kui with the analytical capabilities necessary to innovate in the rapidly evolving fields of statistics and computational biology. Furthermore, Kui earned a Master’s degree in Statistics from the University of Pittsburgh, reinforcing a strong foundation in data analysis essential for developing statistical models and interpretation at a high level.

    Achievements

    In terms of notable achievements, Kui has been at the forefront of precision medicine strategy development specifically tailored for oncology and immune-oncology studies. This commitment to integrating advanced statistical approaches with precision medicine exemplifies a forward-thinking mindset, paving the way for innovative treatment options and improving patient outcomes in cancer care. Recognized for contributions to clinical study development and successful submissions to global health agencies, Kui's proficiency in bridging the gap between statistical knowledge and clinical application remains unmatched. With a focus on enhancing the precision and effectiveness of clinical trials, Kui Shen's work continues to have a profound impact on the scientific community and pharmaceutical industry as a whole.

    Related Questions

    How did Kui Shen contribute to the advancement of precision medicine strategies in oncology?
    What innovative statistical methods has Kui Shen applied in early-stage clinical development?
    In what ways did Kui's education at the University of Pittsburgh and Carnegie Mellon University shape their professional career?
    How has Kui Shen's role as Director of Clinical Statistics at Bayer Pharmaceuticals influenced drug approval processes?
    What experience did Kui Shen gain at AstraZeneca that prepared them for advanced roles in clinical statistics?
    K
    Add to my network

    Location

    New York City Metropolitan Area